ArriVent BioPharma, Inc. 8-K

What Happened
ArriVent BioPharma, Inc. (AVBP) announced its financial results for the quarter ended March 31, 2026 in a press release issued and furnished with an 8-K on May 11, 2026 (Item 2.02). The company filed the press release as Exhibit 99.1 to the Form 8-K (filed under accession number 0001104659-26-058638).

Key Details

• Filing date: May 11, 2026 (Form 8-K reporting results of operations and financial condition, Item 2.02).
• Reporting period: Quarter ended March 31, 2026.
• Disclosure format: Financial results announced via a press release furnished as Exhibit 99.1 to the 8-K.
• Administrative: The 8-K also includes the standard Inline XBRL cover page (Exhibit 104).

Why It Matters
This 8-K signals that ArriVent has issued its quarterly earnings and related financial information; investors should review the furnished press release for the detailed numbers (revenue, expenses, net income/loss, cash position) and any management commentary or outlook. Because the 8-K itself furnishes the release rather than summarizing figures in the body of the filing, the press release (Exhibit 99.1) is the primary source for the company’s reported quarterly results and should be consulted for investment decisions or follow-up analysis.